MedTrace Logo

Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis

NCT01361048 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-01-19

Study results available
· View outcomes & findings →

Summary

The investigators are trying a combination vaginal product of higher dose metronidazole combined with miconazole to see if it is effective in treating vaginal trichomonas.

Conditions

  • Trichomonas Vaginitis

Interventions

DRUG

oral metronidazole

2 gm oral once

DRUG

neo penotran forte

neo penotran forte intravaginal twice a day for 7 days

DRUG

neo penotran forte once a day

neo penotran forte intravaginally once a day for 7 days

Sponsors & Collaborators

  • Embil Pharmaceutical Co. Ltd

    collaborator INDUSTRY

  • University of Alabama at Birmingham

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2012-08-31
Completion
2013-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01361048 on ClinicalTrials.gov